MDACC Study No:2010-0555 ( NCT No: NCT01528384)
Title:A Phase 1 Study of ADI-PEG 20 in Pediatric Subjects Who are Argninosuccinate Synthetase (ASS) Deficient and Have Failed Prior Systemic Therapy
Principal Investigator:Cynthia E. Herzog
Treatment Agent:ADI-PEG 20
Study Status:Terminated
Study Description:The goal of Part 1 of this clinical research study is to learn if a certain
enzyme, called argininosuccinate synthetase, is present in your bone marrow or
tumor tissue. Amino acids are the building blocks that the body uses to make
proteins and enzymes.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma; Pediatrics; Phase I Studies; Solid Tumors
Phase of Study:Phase I
Treatment Agents:ADI-PEG 20
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Polaris Group
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Cynthia E. Herzog
Dept: Pediatrics
For Clinical Trial Enrollment:713-792-6620
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults